July 2024 – Page 37 – Goldea Capital

Rigetti Computing to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Written by Customer Service on July 29, 2024. Posted in Public Companies.

BERKLEY, Calif., July 29, 2024 (GLOBE NEWSWIRE) — Rigetti Computing, Inc. (“Rigetti” or the “Company”) (Nasdaq: RGTI), a pioneer in hybrid quantum-classical computing, announced today that it will release second quarter 2024 results on Thursday, August 8, 2024 after market close. The Company will host a conference call to discuss its financial results and provide an update on its business operations at 4:30 p.m. ET the same day. Key details regarding the call are as follows: Call Date: Thursday, August 8, 2024Call Time: 4:30 p.m. ET / 1:30 p.m. PTWebcast Link: https://edge.media-server.com/mmc/p/p9p5pvoq Live Call Participant Dial-in Number: Toll-Free: 1-888-596-4144 Conference ID: 6114948 Webcast InstructionsYou can listen to a live audio webcast of the conference call by visiting the “Webcast Link”...

Carmell Corporation Appoints New CEO Following Addition to the Russell Microcap Index

Written by Customer Service on July 29, 2024. Posted in Public Companies.

Beauty Pioneer Kendra Bracken-Ferguson Appointed CEO of Carmell Corporation To Champion a Technological Revolution in Regenerative Skincare and Haircare and Build Beauty and Wellness Platform PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) — Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Company” or “Carmell”), today announced the appointment of Ms. Kendra Bracken-Ferguson as Chief Executive Officer effective July 30, 2024 with Mr. Rajiv Shukla continuing to serve as Executive Chairman of the Company. Kendra’s appointment comes at a pivotal moment of growth for the Company. Since its business combination in July 2023, the Company has completed a pivot towards skincare, recruited a top-tier Scientific Advisory Board, developed and tested 12 skincare products aimed at retail and medspa use,...

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Written by Customer Service on July 29, 2024. Posted in Public Companies.

Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients Company advancing toward commencement of Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end Carlsbad, CA, July 29, 2024 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the successful completion of a microbiome study demonstrating that beta-glucuronidase is present at similar levels among dog, mouse, and human microbiota as well as within healthy humans and those with Crohn’s disease (CD) and ulcerative colitis (UC). “We are pleased to bolster our growing...

GenFlat Holdings Announces Up to $7.2 Million Private Securities Offering

Written by Customer Service on July 29, 2024. Posted in Public Companies.

– Rule 506(c) Offering Solely to Accredited Investors – LONG BEACH, Calif., July 29, 2024 (GLOBE NEWSWIRE) — GenFlat Holdings, Inc. (OTC Pink: GFLT), the pioneer in collapsible shipping container technology, today announced a general solicitation private placement offering (“Offering”) solely to accredited investors under Rule 506(c) of Regulation D promulgated by the Securities and Exchange Commission under the Securities Act of 1933, as amended (“Securities Act”). The company intends to use the proceeds from the Offering to fund its anticipated growth including, but not limited to, marketing, business development, research and development, strategic initiatives, manufacturing, inventory and working capital. Details concerning the Offering are included in the company’s offering documents posted on the company’s website...

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

Written by Customer Service on July 29, 2024. Posted in Public Companies.

HUNTSVILLE, July 29, 2024 (GLOBE NEWSWIRE) — Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ PlatformTM drug delivery technology, today announced that Randall Moreadith, MD, Ph.D., Chief Development Officer, will present at the 4th Annual mRNA-Based Therapeutics Summit. The conference will take place from July 29-31, 2024, in Boston, MA. Dr. Moreadith’s presentation, titled “Overcoming Anti-PEG Antibody Responses to Increase Potency & Decrease Adverse Side Effects of mRNA-LNP Formulations”, is scheduled for 9:00 AM ET on Monday, July 29. In this talk, Dr. Moreadith will present novel data on Serina Therapeutics’ innovative POZ-lipid, a proprietary technology that aims to significantly advance the safety and efficacy of mRNA-LNP formulations....

Citizens Community Bancorp, Inc. Reports Second Quarter 2024 Earnings of $0.35 Per Share; Board of Directors Approves Additional 5% Stock Buyback Authorization; Criticized Assets Decreased 18%

Written by Customer Service on July 29, 2024. Posted in Public Companies.

EAU CLAIRE, Wis., July 29, 2024 (GLOBE NEWSWIRE) — Citizens Community Bancorp, Inc. (the “Company”) (Nasdaq: CZWI), the parent company of Citizens Community Federal N.A. (the “Bank” or “CCFBank”), today reported earnings of $3.7 million and earnings per diluted share of $0.35 for the second quarter ended June 30, 2024, compared to $4.1 million and earnings per diluted share of $0.39 for the quarter ended March 31, 2024, and $3.2 million and $0.31 earnings per diluted share for the quarter ended June 30, 2023, respectively. The Company’s second quarter 2024 operating results reflected the following changes from the first quarter of 2024: (1) lower nonaccrual interest income of $0.4 million recognized in net interest income in the second quarter relative to the first quarter; (2) a $0.73 million increase in negative provision for...

Skyharbour Signs Agreement to Sell a Portion of its Karin Uranium Property to Cosa Resources Corp.

Written by Customer Service on July 29, 2024. Posted in Public Companies.

Vancouver, BC, July 29, 2024 (GLOBE NEWSWIRE) — Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQX: SYHBF) (Frankfurt: SC1P) (“Skyharbour” or the “Company”), is pleased to announce that it has entered into a property purchase and sale agreement (the “Agreement”) with Cosa Resources Corp. (“Cosa”) dated July 26th, 2024, whereby Skyharbour will sell Cosa two (2) mineral claims, comprising approximately 6,049 hectares. These two claims represent a small portion of Skyharbour’s Karin Property and are located in Saskatchewan about 22 km south of the Key Lake Mill. In consideration for the claims, Cosa will issue to Skyharbour 250,000 common shares in the capital of Cosa (the “Consideration Shares”). Skyharbour originally acquired the claims through low-cost, online staking. The Company retains ownership in five other adjacent claims constituting...

Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts

Written by Customer Service on July 29, 2024. Posted in Public Companies.

PARSIPPANY, NJ, July 29, 2024 (GLOBE NEWSWIRE) — Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the undefined extension granted by Centers for Medicare & Medicaid Services (CMS) to Novitas, its Medicare Administrative Contractor (MAC). Novitas announced late last week that CMS granted an extension to the final decision for Local Coverage Determination (LCD) of Genetic Testing for Oncology (L39365) in order for all comments received in response to the proposed changes to be thoroughly considered. LCD (L39365) includes PancraGEN®, a DNA-based diagnostic molecular test. It uniquely assesses the risk of pancreatic cyst progression to cancer by integrating the results of first-line tests and procedures with molecular test results. Dr. Nicole Massoll,...

Canadian GoldCamps Announces Voting Results from Annual General and Special Meeting

Written by Customer Service on July 29, 2024. Posted in Public Companies.

TORONTO, July 29, 2024 (GLOBE NEWSWIRE) — Canadian GoldCamps Corp. (“Canadian GoldCamps”, or the “Company”) (CSE: CAMP) (FSE: A68) (OTC: SMATF) is pleased to announce the results of voting at its Annual General and Special Meeting of Shareholders held July 26, 2024 (the “Meeting”). At the Meeting, Shareholders voted in favour of all items put forward by the Company in the management information circular dated June 25, 2024. Michael Taylor, Maciej Lis and Jason Hawkins were all elected to the board of directors. Shareholders also voted in favour of: re-appointing Stern & Lovrics LLP, as auditors of the Company for the ensuing year and authorizing the directors to fix their remuneration; approving the Company’s Omnibus Long-term Incentive plan; authorizing the Company to conduct a non-brokered private placement; and authorizing...

TX Rail Products, Inc. Reports Fiscal 2024 Third Quarter Results

Written by Customer Service on July 29, 2024. Posted in Earnings Releases And Operating Results.

Gross margin expands to nearly 30%Net income increases 63% year-over-year ASHLAND, Ky., July 29, 2024 (GLOBE NEWSWIRE) — TX Rail Products, Inc. (OTC Markets PINK: TXRP), a supplier of rail and rail products to the U.S. coal mining industry, short line railroads and tunneling contractors, today announced financial results for its third quarter of fiscal year 2024. Mr. Shrewsbury, CEO and Chairman of TX Rail Products, Inc., commented, “With a 63% year-over-year increase in net income in the third quarter of fiscal 2024, we have delivered our ninth consecutive quarter of positive earnings despite a modest decline in revenue. We have successfully reduced our cost of goods to drive our gross margin to nearly 30%, which we believe is sustainable, and we are generating positive cash from operations. We are optimistic about the outlook...

Month: July 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice